Northstrive Biosciences Advances AI-Powered Drug Discovery for Obesity and Cardiac Diseases
- Northstrive Biosciences has initiated Phase II of its collaboration with Yuva Biosciences to develop AI-powered therapies targeting mitochondrial health in obesity and cardiac diseases.
- The partnership leverages MitoNova™, YuvaBio's proprietary AI platform, to screen large-scale libraries of small molecules and identify candidates that promote mitochondrial health.
- The collaboration aims to compile synthetic compounds for muscle preservation and metabolic health, addressing the root cause of aging and related conditions at the cellular level.
- Northstrive's lead asset EL-22 uses an engineered probiotic approach to preserve muscle mass during weight loss treatments, including GLP-1 receptor agonist therapies.